Zevra Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:ZVRA

Comments

Zevra Therapeutics Inc Earnings Estimates

ZVRANASDAQ

Trade with Public

$9.99

0.212.09%

Last update: Apr 15, 12:25 PM

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

Zevra Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:ZVRA

Zevra Therapeutics (ZVRA) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $0.07 and quarterly revenue of $31.72M.

In the most recent quarter (Q4), Zevra Therapeutics reported EPS of $0.19, beating estimates of $0.05 by 2.80%. Revenue came in at $34.13M, exceeding the estimate of $28.00M by 0.22%.

Zevra Therapeutics has beaten EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Zevra Therapeutics has averaged an EPS surprise of 1.07% and a revenue surprise of 0.15%.

Earnings Date

May 12

EPS Estimate

$0.070

Quarterly Revenue Estimate

$31.72M

Annual Revenue
(as of Dec 31)

$106.47M

Zevra Therapeutics Earnings History

Analyze the earnings history of Zevra Therapeutics using advanced sorting and filters.

Loading calendar...

Zevra Therapeutics (ZVRA) Earnings Per Share

The chart below shows Zevra Therapeutics's reported EPS compared to analyst estimates over recent quarters.

Zevra Therapeutics (ZVRA) Revenue

The chart below shows Zevra Therapeutics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Zevra Therapeutics (NASDAQ:ZVRA) reporting earnings?

Zevra Therapeutics (ZVRA) is scheduled to report earnings on May 12, 2026. The last reported earnings were for reported on March 9, 2026 for Q4.

What were the latest earnings per share (EPS) for Zevra Therapeutics (NASDAQ:ZVRA)?

The Actual EPS was $0.19, which beat the estimate of $0.05.

What were Zevra Therapeutics’s (NASDAQ:ZVRA) revenues?

The Actual Revenue was $34.13M, which beat the estimate of $28.00M.

People Also Watch

Atea Pharmaceuticals Inc

NASDAQ:AVIR

$5.70

-0.26%

Theravance Biopharma Inc

Neumora Therapeutics Inc

NASDAQ:NMRA

$2.01

-1.72%

Aquestive Therapeutics Inc

NASDAQ:AQST

$4.18

0.60%

Esperion Therapeutics Inc

NASDAQ:ESPR

$2.11

2.68%

Zevra Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:ZVRA

Zevra Therapeutics (ZVRA) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $0.07 and quarterly revenue of $31.72M.

In the most recent quarter (Q4), Zevra Therapeutics reported EPS of $0.19, beating estimates of $0.05 by 2.80%. Revenue came in at $34.13M, exceeding the estimate of $28.00M by 0.22%.

Zevra Therapeutics has beaten EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Zevra Therapeutics has averaged an EPS surprise of 1.07% and a revenue surprise of 0.15%.

Earnings Date

May 12

EPS Estimate

$0.070

Quarterly Revenue Estimate

$31.72M

Annual Revenue
(as of Dec 31)

$106.47M